© 2023 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#follicular lymphoma

Lymphocytes attacking cancer cells
What Is Lymphoma?
FDA Approved stamp
FDA Approves Tazverik for Follicular Lymphoma
Unidentified hand connected to a chemo therapy treatment
All Approved Medications to Treat Lymphoma

Now Approved Cancer Drugs — Spring 2023

Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.

FDA Approves Lunsumio for Treatment of Follicular Lymphoma

Mosunetuzumab is the first bispecific antibody, a type of immunotherapy, approved to treat non-Hodgkin lymphoma.

New Lymphoma Drug Shows Promise in Clinical Trials

Eighty percent of participants with relapsed follicular lymphoma responded to a new drug.

New COVID Vaccine May Better Protect Cancer Patients

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.
Yescarta being prepared in a laboratory.

FDA Approves Yescarta for Follicular Lymphoma

The CAR-T therapy led to complete remission in 60% of people with relapsed or refractory follicular lymphoma.
T cells attack a cancer cell

FDA Approves New CAR-T Therapy for Large B-Cell Lymphoma

Half of patients treated with Breyanzi experienced complete remission, and a majority of these responses were durable.

FDA Approves Ukoniq for Marginal Zone and Follicular Lymphoma

Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.

Rituxan

Tazverik

FDA Approves Revlimid for Follicular and Marginal Zone Lymphoma

Approval was based on the results of two clinical trials: AUGMENT and MAGNIFY.

Gazyva

Aliqopa

A patient’s T cells arrive at the Novartis manufacturing facility in Morris Plains, where they will be re-engineered to recognize and fight cancer and healthy cells expressing a specific antigen in the patient’s body.

FDA Approves Kymriah for Adults with Relapsed or Refractory Large B-Cell Lymphoma

The overall response rate was 50%, with a complete response rate of 32%.

FDA Approves Kymriah CAR-T Therapy for Lymphoma

The custom immunotherapy is now indicated for adults with relapsed or refractory lymphoma.
A patient’s T cells arrive at the Novartis manufacturing facility in Morris Plains, where they will be re-engineered to recognize and fight cancer and healthy cells expressing a specific antigen in the patient’s body.

Kymriah CAR-T Therapy Leads to Long-Term Remission in Adults With Lymphoma

Findings from the JULIET trial support expanded Food and Drug Administration approval of customized T cells.

FDA Approves Obinutuzumab for Previously Untreated Follicular Lymphoma

FDA grants regular approval to obinutuzumab (Gazyva) for adults with previously untreated follicular lymphoma.
Advertisement
Science News
Blog: Damon Runyon Cancer Research Foundation

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Cancer Health uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.